Latest Conference Coverage

Interim data from the SPOTLIGHT study were presented at the ASCO GU Symposium.

Updated data were presented on LYS-SAF302 and LYS-GM101 at WORLDSymposium.

The director of research and development at AVROBIO discussed the analytical pipeline the company has developed for molecular follow-up of cell therapies.

The associate professor from UC San Diego discussed the curative potential of gene therapy in cystinosis.

Passage Bio presented data on both the Krabbe and GM1 gangliosidosis programs at WORLDSymposium.

Interim safety data from the FORTIS study were presented at WORLDSympsoium.

The senior vice president of clinical development at Passage Bio discussed new data from the IMAGINE-1 trial presented at WORLDSymposium.

AVROBIO presented data on their analytical pipeline and exploratory studies of molecular follow-up from their lentiviral cell therapy products.

Positive results from a phase 1/2 study of AXO-AAV-GM1 were presented at WORLDSymposium.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Interim data from trials of RGX-121 and RGX-111 were presented at WORLDSymposium 2022.

The hematologist/oncologist from Mayo Clinic discussed targeting HLA loss in solid tumors.

The LV-HSCGT therapy has demonstrated efficacy in preclinical studies in mouse models.

The clinical professor of medicine, Helen Diller Family Comprehensive Cancer Center, UCSF, discussed data from both the CARTITUDE-1 and CARTITUDE-2 studies.

The medical director of Bone Marrow Transplantation and Immune Deficiency at Cincinnati Children's discussed data on ARU-1801 presented at ASH 2021.

The SURPASS-2 trial will run parallel to the ongoing SURPASS trial.

The hematologist/oncologist from Mayo Clinic discussed advantages of Tmod cell therapy in solid tumors.

The BASECAMP-1 study is identifying patients for future use of Tmod CAR T-cell therapies.

The director of the hemostasis and thrombosis program at Children’s Hospital Los Angeles discussed advantages of the siRNA therapeutic.

Data from the phase 2 QUILT-88 study were presented at the 2022 ASCO GI symposium.

Carisma Therapeutics and Moderna are also collaborating to develop CAR-M cell therapies.

Further details on the KEYNOTE-B79 trial were presented at the 2022 ASCO GI Symposium.

Greg Kunst, chief executive officer, Aurion Biotech, discussed the potential of cell therapy in treating people with corneal endothelial disease around the world.

The clinical professor of medicine, Helen Diller Family Comprehensive Cancer Center, UCSF, discussed data from the CARTITUDE-1 study presented at ASH 2021.

The hematologist/oncologist from Mayo Clinic discussed advantages of Tmod technology in solid tumors.

Cedrik Britten, MD, chief medical officer, Immatics, discussed the advantages of IMA203 over other cell therapies.

Details on the phase 1/2 CEDAR trial were presented at the 2021 ASH meeting.

The director of the hemostasis and thrombosis program at Children’s Hospital Los Angeles discussed improving outcomes in hemophilia with fitusiran.